OR7C1

Across TCGA pan-cancer cohorts, OR7C1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR7C1 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR7C1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR7C1 expression acts as an unfavorable survival marker.

OV, STAD, and LUSC are the cancer types where OR7C1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
STAD	OS	Median	II,III,IV	0.184	0.710	.001	12	view →
LUSC	OS	Median	All	0.150	0.724	.005	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

OR7C1–OV (DFS)

Open the OV breakdown →